{
    "info": {
        "nct_id": "NCT06524375",
        "official_title": "Phase II, Open-Label, Prospective Single-Arm, Multi-Center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-Treatment Period.",
        "inclusion_criteria": "1. Diagnosed with CLL and currently receiving a stable dose of cBTKi (i.e., ibrutinib, acalabrutinib, or zanubrutinib) for at least 6 months for 1L treatment with a response of at least a PR per iwCLL criteria\n2. Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to (</=) 2\n3. Adequate renal and liver function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Prior B-cell lymphoma (Bcl-2) inhibitor therapy\n2. Progressive or stable disease on cBTKi\n3. Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (Richter's transformation or pro-lymphocytic leukemia)\n4. History of cardiomyopathy\n5. Hypersensitivity to venetoclax or to any of the excipients (e.g., trehalose)\n6. Clinically significant cardiovascular disease\n7. Active bleeding or history of bleeding diathesis\n8. Pregnant women and nursing mothers\n9. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to (</=) 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to (</=) 2",
                    "criterion": "ECOG performance score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Diagnosed with CLL and currently receiving a stable dose of cBTKi (i.e., ibrutinib, acalabrutinib, or zanubrutinib) for at least 6 months for 1L treatment with a response of at least a PR per iwCLL criteria",
            "criterions": [
                {
                    "exact_snippets": "Diagnosed with CLL",
                    "criterion": "chronic lymphocytic leukemia (CLL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "currently receiving a stable dose of cBTKi (i.e., ibrutinib, acalabrutinib, or zanubrutinib)",
                    "criterion": "cBTKi therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stability of dose",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug names",
                            "expected_value": [
                                "ibrutinib",
                                "acalabrutinib",
                                "zanubrutinib"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for at least 6 months",
                    "criterion": "duration of cBTKi therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for 1L treatment",
                    "criterion": "line of therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment line",
                            "expected_value": "first line"
                        }
                    ]
                },
                {
                    "exact_snippets": "with a response of at least a PR per iwCLL criteria",
                    "criterion": "treatment response per iwCLL criteria",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "PR (partial response)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Adequate renal and liver function",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... liver function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "1. Prior B-cell lymphoma (Bcl-2) inhibitor therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior B-cell lymphoma (Bcl-2) inhibitor therapy",
                    "criterion": "B-cell lymphoma (Bcl-2) inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Progressive or stable disease on cBTKi",
            "criterions": [
                {
                    "exact_snippets": "Progressive or stable disease on cBTKi",
                    "criterion": "disease status on cBTKi",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "progressive",
                                "stable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Clinically significant cardiovascular disease",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled autoimmune hemolytic anemia",
                    "criterion": "autoimmune hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... immune thrombocytopenia",
                    "criterion": "immune thrombocytopenia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Pregnant women and nursing mothers",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing mothers",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (Richter's transformation or pro-lymphocytic leukemia)",
            "criterions": [
                {
                    "exact_snippets": "Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (Richter's transformation or pro-lymphocytic leukemia)",
                    "criterion": "transformation of CLL",
                    "requirements": [
                        {
                            "requirement_type": "transformation type",
                            "expected_value": [
                                "aggressive non-Hodgkin lymphoma (NHL)",
                                "Richter's transformation",
                                "pro-lymphocytic leukemia"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Hypersensitivity to venetoclax or to any of the excipients (e.g., trehalose)",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity to venetoclax",
                    "criterion": "hypersensitivity to venetoclax",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensitivity ... to any of the excipients (e.g., trehalose)",
                    "criterion": "hypersensitivity to excipients (e.g., trehalose)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Active bleeding or history of bleeding diathesis",
            "criterions": [
                {
                    "exact_snippets": "Active bleeding",
                    "criterion": "bleeding",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of cardiomyopathy",
            "criterions": [
                {
                    "exact_snippets": "History of cardiomyopathy",
                    "criterion": "cardiomyopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}